We have investigated the effects of acute promyelocytic leukemia (APL) fusion gene NPM-RARa on the function of PPARc using the monoblastic cell line U937. U937 cells were transduced using a retrovirus carrying NPMRARa. While treatment with the synthetic PPARc ligand troglitazone (TG) had no effect on the viability of U937 cells, TG treatment of U937/NPM-RARa cells resulted in a dramatic decrease in cell viability, dependent upon both the concentration of TG and the level of expression of NPM-RARa. Analysis of the cell cycle profile and flow cytometry with annexin V confirmed that these effects of TG were due to induction of apoptosis. Induction of apoptosis was accompanied by caspase-8 and caspase-9 activation, and could be blocked by treatment with the caspase inhibitor Z-VAD-FMK. Cotreatment of U937/ NPM-RARa cells with all-trans retinoic acid (atRA) abrogated the induction of apoptosis by TG. Induction of apoptosis was seen also in the PML-RARa-expressing APL cell line NB4, and in several other atRA-sensitive leukemia cell lines, demonstrating that this effect is limited neither to the monocyte lineage nor to the rare NPM-RARa fusion variant. RXRa/NPM-RARa heterodimers were found to interact directly with a PPARcresponsive element in vitro. We conclude that in the presence of X-RARa, TG induces cell death due to apoptosis via the caspase pathway. These observations suggest the investigation of PPARc ligands as therapeutic agents in acute leukemia.
Introduction
Human acute promyelocytic leukemia (APL) is characterized by the presence of chromosome translocations involving the retinoic acid receptor a (RARa) gene on chromosome 17 (Alcalay et al., 1991; . At least five different fusion partners for RARa have been described, involving the PML, PLZF, NPM, NuMA and STAT5b genes (Melnick and Licht, 1999; Zelent et al., 2001) . The block to granulocytic differentiation in APL is overcome by high pharmacological concentrations of all trans retinoic acid (atRA). Although the effects of X-RARa on the retinoids and retinoic acid receptor signaling in hematopoiesis have been extensively studied, the potential effects on signaling through other nuclear receptors remain largely uncharacterized.
The peroxisome proliferator-activated receptors (PPARs) are members of a nuclear receptor superfamily of ligand-activated transcriptional factors that include receptors for steroids, thyroid hormone, vitamin D and retinoic acid (Mangelsdorf et al., 1995) . The PPAR family is comprised of three subtypes termed PPARa, PPARb (also termed PPARd) and PPARg. Each PPAR is encoded by a different gene and shows tissue-specific distribution and function. PPARa is highly expressed in liver, heart, proximal tubules of the kidney and enterocytes, while PPARb is more widely and often abundantly expressed (Kliewer et al., 1994; Mangelsdorf et al., 1995; Braissant et al., 1996) . PPARg is expressed at high levels in adipose tissue, adrenal gland and spleen. It plays a critical role in adipocyte differentiation and glucose metabolism (Kliewer et al., 1994 . PPARg is also expressed in components of the immune system, including monocytes and bone marrow precusors (Vamecq and Latruffe, 1999) . PPARg binds to peroxisome proliferator-responsive elements (PPREs) as a heterodimer with the retinoid X receptor (RXR) (Gearing et al., 1993) . This heterodimer is activated by PPARg ligands, such as 15-deoxy-delta 12, 14 -prostaglandin J 2 (15d-PGJ 2 ), a natural ligand for PPARg and thiazolidinediones (TZDs), chemically synthesized ligands for PPARg. TZDs including troglitazone (TG), pioglitazone and BRL49653 have been used as novel antidiabetic agents for the treatment of hyperglycemia and insulin resistance in type II diabetes .
Many types of cells and tissues that express PPARg may thus be regulated through ligand-induced activation. Tontonoz et al. (1998) reported that TZD derivatives, together with the specific ligands of RXR, mediated signals which induced the differentiation of hematopoietic cells to the monocyte/macrophage lineage. Other studies have shown that PPARg ligand can induce terminal differentiation of human liposarcoma (Tontonoz et al., 1997) . Since this initial study, PPARg expression and activation have been noted in other carcinomas. Recent studies have shown that PPARg ligands inhibited cell growth and induced the apoptosis of human lung cancer (Tsubouchi et al., 2000) , breast cancer (Elstner et al., 1998 (Elstner et al., , 2002 Mueller et al., 1998) , colon cancer (Kitamura et al., 1999) and pancreatic cancer cells (Eibl et al., 2001) . In hematopoietic cells, peripheral mononuclear cells and several human leukemia cell lines have been reported to express PPARg (Greene et al., 1995) . TZD initiates monocytic differentiation in the promyelocytic leukemia cell line HL60 and induces apoptosis at a high concentration (Hirase et al., 1999) . PPARg expression and its significance in apoptosis have also recently been evaluated in human B lymphocytes (Padilla et al., 2002) . In the present study, we have investigated the effects of the APL fusion gene NPM-RARa on the function of PPARg using the monoblastic cell line U937. We demonstrate that expression of NPM-RARa, in which RARa is fused in frame to the nucleophosmin gene, in U937 cells alters the response of these cells to TG, inhibits cell growth and induces apoptosis through both mitochondrial and receptor-mediated pathways.
Results

Expression of U937/NPM-RARa protein
Studies of the structure and function of rare APL gene fusions have proved useful in elucidating the biology of this disease. The PML-RARa-expressing cell line, NB4, is a widely used tool in this field, but no cell line models expressing X-RARa variant fusions exist. We used retroviral transfer of the NPM-RARa fusion, which we had previously cloned (Hummel et al., 1999) , to create such a model. U937 cells were stably infected using a retroviruscarrying V5-tagged NPM-RARa. We isolated 60 single clones from a mixed cell population. After the detection of GFP percentage by flow cytometry, only 26 clones exhibited GFP expression in greater than 85% of cells. We examined the expression of NPM-RARa protein in all these clones. Expression of NPM-RARa protein was determined by Western blot analysis using anti-V5 antibody. NPM-RARa protein was detectable in 17 clones. As shown in Figure 1a , the NPM-RARa protein showed the expected molecular weight of approximately 57 kDa. NPM-RARa expression was normalized against a-actin by densitometry. As shown in Figure 1b , each individual clone and the mixed population expressed different levels of NPM-RARa protein. Cells infected with GFP as a control did not express NPM-RARa protein. NPM-RARa mix1 and NPM-RARa mix2 each represent a mixed population which express NPM-RARa protein at a relatively low level. NPM-RARa55 has the highest expression, and is defined as a high expressor. NPM-RARa18 and NPM-RARa34 also express NPMRARa at a relatively high level, while NPM-RARa46, NPM-RARa13 and NPM-RARa40 have low expression of NPM-RARa protein and are labeled as low expressors.
NPM-RARa expression blocks 1,25(OH) 2 D 3 -induced cell differentiation U937 cells are morphologically primitive, but can be induced to undergo monocytic differentiation by exposure to a variety of agents including 1,25(OH) 2 D 3 , the ligand for the vitamin D receptor (VDR). It has previously been reported that forced expression of the PML-RARa fusion in U937 cells blocks this VDRmediated differentiation (Testa et al., 1994) . To establish that NPM-RARa exerts a similar effect, we incubated U937/GFP control and U937/NPM-RARa cells with 2.5 Â 10 À7 M 1,25(OH) 2 D 3 for 5 days. Expression of cell surface antigen and morphological changes were used as markers of differentiation. Expression of CD11b and CD14 was markedly induced in U937 and U937/GFP 
Effect of TG on proliferation
In addition to VDR, signaling through another nuclear receptor, PPARg, has been shown to play a role in monocyte development . Although transient transfection experiments have indicated that PML-RARa may interfere with PPARg signaling (Jansen et al., 1995) , the effects of X-RARa fusions on differentiation and function of monocytes have not been delineated. We therefore investigated the effects of NPM-RARa on PPARg signaling in U937 cells with and without NPM-RARa expression, using the synthetic PPARg ligand TG. We first compared the growth of U937/GFP control and U937/NPM-RARa clones. As shown in Figure 4a , a moderate inhibition of cell growth was observed in U937/NPM-RARa clones, with high expressor showing the strongest inhibition. We also examined the effect of TG on the growth of these cells, as shown in Figure 4b . TG caused a dramatic decrease in viable cells, which depended on TG concentration and the time of drug exposure. Inhibition of growth for U937/NPM-RARa cells was evident at day 2 at a concentration of 7.5-30 mM TG, and after 4 days in culture at 30 mM, cell growth was completely suppressed. In cell viability experiments, we found that cell death with TG occurred in a time-dependent manner, suggesting that TG may induce cell apoptosis. Once again, the largest TG-induced decline in viability occurred in clones expressing relatively high levels of NPM-RARa. These results indicate that NPM-RARa is 
Cell cycle analysis in U937/NPM-RARa cells
To determine whether the effect of PPARg activation by TG was mediated by an induction of apoptosis, we used flow cytometry to examine cell cycle profiles. The percentage of cells in the sub-G0/G1 area increased as the concentration of TG increased (data not shown). Analysis of the cell cycle was performed after their exposure to TG at 30 mM for 72 h. The percentage of either U937/GFP control or U937/NPM-RARa cells in the sub-G0/G1 region, reflecting apoptotic and dead cells, is given for each clone as shown in Figure 5 . The percentage of apoptotic cells is increased significantly following TG treatment for the high NPM-RARaexpressing clones, 18 (2.6 versus 64.3%) and 55 (2.5 versus 67.5%), compared to the low expressor 46 (3.0 versus 14.7%) and GFP control clone (2.0 versus 2.9%).
In addition, the proportion of the sub-G0/G1 fraction was synergistically increased after combined treatment with 30 mM TG and 1 mM atRA for the low expressor 46 (14.7-26.4%) and GFP control (2.9-5.0%). In contrast, the percentage of cells in the sub-G0/G1 fraction was decreased after combined treatment with TG and atRA in the high expressing clones 18 (64.3-17.7%) and 55 (67.5-31.4%). Taken together, these results suggest that ligand activation of PPARg strongly induces apoptosis of U937/NPM-RARa cells; unexpectedly, this effect is abrogated by the addition of atRA.
TG induces apoptosis in U937/NPM-RARa cells
To confirm that TG kills U937/NPM-RARa cells by inducing apoptosis, we first examined the translocation of phosphatidyserine (PS) from the inner leaflet of the plasma membrane to the outer leaflet by annexin V-PE labeling. Annexin V is a Ca 2 þ -dependent phospholipidbinding protein with high affinity for PS (Vermes et al., 1995) . Staining with annexin V-PE in conjunction with 7-AAD is a sensitive method for detecting cells that are undergoing early phases of apoptosis. Viable cells are double negative (annexin V-PE À /7-AAD À ). Cells at an early stage of apoptosis are positive for annexin V-PE but negative for 7-AAD (annexin V-PE þ /7-AAD À ). Cells at a late stage of apoptosis (necrosis) are double positive (annexin V-PE þ /7-AAD þ ). U937/GFP control, U937/NPM-RARa clone 18, 55 and 46 were left untreated or were treated with 30 mM TG for 24, 48 and 72 h ( Figure 6 ). Untreated cells were annexin V-PE and 7-AAD negative, indicating that they were viable and not undergoing apoptosis. No change was observed at 24 h after treatment with TG. High expressing clones underwent apoptosis 48 h following treatment, with 39.4% (NPM-RARa 18) and 15.2%(NPM-RARa 55) being positive for annexin V binding, and this reached 99.7 and 95.1%, respectively, at 72 h. Low expressing clone NPM-RARa 46 also underwent apoptosis 72 h following treatment (58.6% annexin V positive), whereas the GFP control showed apoptosis in only 12.6% of cells at 72 h. These data indicate that the PPARg agonist TG cooperates with NPM-RARa to induce apoptosis in U937 cells.
TG activates caspases in U937/NPM-RARa cells
The caspases, a family of aspartate-specific cysteine proteases, play a pivotal role in the execution of programmed cell death (Nicholson and Thornberry, 1997) . To determine more directly whether caspase activation is indispensable for TG-induced apoptosis, a Troglitazone induces apoptosis in the presence of X-RARa S Kamel-Reid et al general peptide inhibitor of caspases, Z-VAD-FMK, was used. As shown in Figure 7a , pretreatment of U937/NPM-RARa 18 (high expressor) with 100 mM of Z-VAD-FMK for 1 h completely inhibited TGinduced cell death by cell cycle analysis. To elucidate the pathways involved in the observed apoptosis, we measured the intracellular caspase-8 and caspase-9 activity at various time points after treating cells with 30 mM of TG. We tested the processing of procaspases by immunoblot analysis using antibodies specific to individual proteases. First, we investigated the processing of caspase-8, the most proximal caspase during death receptor-mediated apoptosis (Nagata, 1997) . Caspase-8 is first synthesized as inactive isoforms of about 55/50 kDa, which after the formation of an intermediate cleaved form of 40/36 kDa is processed into P23 and P18 active forms. When we immunoblotted our clones with antibodies against both the proform and cleaved forms, we found that TG treatment resulted in cleavage of caspase-8 into its intermediate form for NPM-RARa clones as shown in Figure 7b . The cleaved products were increased time dependently from 24 to 72 h. For the highest expressor, NPM-RARa 55, the P23 and P18 active forms could be observed at 48 h, and peaked at 72 h. In contrast, we did not detect any cleaved products of caspase-8 in the GFP control even at 72 h after treatment. This indicates that the caspase-8 pathway is activated in U937 only in the presence of NPM-RARa. Next, we tested for the activation of caspase-9, which is believed to transfer the death signal from the mitochondria (Kuida, 2000) . As shown in Figure 7b , caspase-9 was cleaved to generate a 37 kDa active form in U937/NPM-RARa cells, but not in U937/ GFP control cells. This also occurred in a timedependent manner. These results confirm that TG induces apoptosis in NPM-RARa-expressing clones through activation of both caspase-8 and caspase-9 pathways.
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-TG +TG +atRA +TG Figure 5 Cell cycle profile by PI staining. U937/NPM-RAR clones and U937/GFP control cells were cultured in the absence or presence of TG (30 mM) or combination of TG (30 mM) and atRA (1 mM) for 3 days, and stained with PI, then analysed by flow cytometry. The percentage of cells in the sub-G0/G1 region, reflecting apoptotic and dead cells, is given for each clone. Note that this percentage is increased following TG treatment and recovered with the combination of TG and atRA for the high NPM-RAR expressing clones (18, 55), compared to the low expressor 46 and GFP control. NR represents NPM-RAR Troglitazone induces apoptosis in the presence of X-RARa S Kamel-Reid et al
TG-induced apoptosis in other leukemia cell lines
To investigate whether induction of apoptosis by TG could be observed in other cell types, we tested the APL cell line NB4 and the acute myelogenous leukemia (AML) cell line HL60 using FACS analysis (Figure 8 ). NB4 cells, which express PML-RARa, showed a response strikingly similar to that of U937/NPM-RARa cells, with 67.1% of cells found in the sub-G0/G1 compartment after 48 h incubation with 30 mM TG. As in U937/NPM-RARa-expressing cells, the TG effect could be blocked by coincubation of the cells with 1 mM atRA. The non-APL leukemia cell line HL60 was also TG sensitive, with 37.4% of cells in the sub-G0/G1 at 48 h. However, HL60 cells were not rescued from TGinduced apoptosis by atRA treatment. Indeed, the proportion of sub-G0/G1 cells was increased to 78.0% after cotreatment of HL60 cells with atRA and TG. The observation of TG-induced apoptosis in HL60 cells is surprising. Although HL60 cell have promyelocyte morphology and undergo neutrophil maturation when treated with retinoic acid, they do not express an APL fusion protein. We surmised that other non-APL but retinoid-sensitive acute myelogenous leukemia (AML) cells might also exhibit TG-induced apoptosis.
As shown in Figure 9 , we tested five OCI/AML cell lines using FACS analysis. The most retinoid-sensitive of these cell lines, AML1, AML2, and AML3, underwent TG-induced apoptosis, with 26.9-54.0% of cells in the sub-G0/G1 compartment after 72 h incubation with 30 mM TG. In contrast, the relatively RA-insensitive line AML4 was insensitive also to TG, while AML5 cells showed modest sensitivity.
Mechanism of TG-induced apoptosis
The sensitization of cells to induction of apoptosis by TG is an unexpected finding. We conjectured that the APL fusion proteins interfere directly with PPARg signaling, and in this way corrupt the response to TG. To test this hypothesis, we performed a functional assay using a luciferase reporter construct under the control of a PPARg-responsive element (PPRE). This reporter was activated by TG when transiently transfected into COS-7 cells (Figure 10a ). However, TG activation of the reporter was blocked when an NPM-RARa expression plasmid was cotransfected with the reporter plasmid.
Since neither NPM-RARa homodimers nor RXRa/ NPM-RARa heterodimers are predicted to bind effectively to the PPRE, it is not obvious how NPM-RARa Troglitazone induces apoptosis in the presence of X-RARa S Kamel-Reid et al might block PPARg signaling. To investigate the possibility of direct interaction between NPM-RARa and PPRE DNA sequences, we performed electrophoretic mobility-shift assays (EMSA) using in vitro translated NPM-RARa and RXRa and a radiolabeled PPRE oligonucleotide (Figure 10b) . Unexpectedly, we observed that RXRa/NPM-RARa heterodimer does bind to the PPRE.
Discussion
Studies of the effects of the APL fusion proteins have previously focused on their impact on granulocyte differentiation as mediated by RARa. We have developed an experimental approach that permits analysis of the effects of the APL fusions on development of the monocyte lineage, and we have employed this approach A similar response to TG is observed in the APL cell line NB4, indicating that this effect on TG-mediated signaling is limited neither to the variant NPM-RARa fusion, nor to the monocyte lineage. Unexpectedly, five of six non-APL AML cell lines also exhibit TG-induced apoptosis, with the degree of TG sensitivity of the cells corresponding to their retinoid sensitivity. We find that expression of NPM-RARa blocks the activity of a TGresponsive reporter plasmid in transient transfection assays, and that RXRa/NPM-RARa heterodimers bind a PPARg response element in vitro. These observations will permit further elucidation of the link between PPARg signaling and apoptosis, and point to a potential therapeutic utility of PPARg ligands in APL. U937 monoblast cells have been utilized extensively for the study of monocytic differentiation induced by retinoid acid (Atsumi et al., 1986) , 1,25(OH) 2 D 3 (Rigby et al., 1984) and 12-O-tetradecanoylphorbol-13 acetate (TPA) (Hass et al., 1989) . In the present study, we demonstrate that 1,25(OH) 2 D 3 alone can induce U937 cells to differentiate along the monocytic lineage with upregulation of CD11b and CD14, and that expression of the NPM-RARa fusion gene blocks this differentiation. However, no changes of CD11b, CD14 and CD36 were observed when the same experiment was performed with cells treated with 15 mM and 30 mM TG. Previous studies have shown TG-induced monocytic differentiation in HL60 cells (Fujimura et al., 1998; Asou et al., (Pizzimenti et al., 2002) . Our data are in agreement with this observation, suggesting that the induction of monocytic differentiation by TG is cell-type specific.
We investigated the effect of TG on proliferation of U937 cells in this study. TG exhibited a dose-and timedependent growth inhibition effect on U937 cell lines, consistent with observations in other leukemia cell lines (Fujimura et al., 1998; Asou et al., 1999) . In addition, this inhibition effect is correlated to the expression level of NPM-RARa. Western blot data showed that different clones expressed different levels of NPM-RARa protein. Clones expressing high levels of NPM-RARa showed an earlier and stronger inhibition effect of TG, whereas lower expressing clones and controls showed a later and less-pronounced effect on growth. The difference in sensitivity to TG can thus be explained by the difference in the expression level of NPM-RARa, although the mechanism through which this occurs remains to be elucidated.
The TG-induced decrease in cell viability resulted from the induction of apoptosis, as confirmed by FACS and the appearance of annexin V positive cells. Apoptosis induction by PPARg ligands has been demonstrated in a variety of cell lines (Elstner et al., 1998 (Elstner et al., , 2002 Mueller et al., 1998; Kitamura et al., 1999; Takahashi et al., 1999; Chang and Szabo, 2000; Padilla et al., 2000; Tsubouchi et al., 2000; Eibl et al., 2001 , Kawa et al., 2002 . In the HL60 leukemia cell line, TG suppressed cell proliferation and induced apoptosis at concentrations of 25-50 mM (Hirase et al., 1999) , which were similar to what we used in our experiment. The authors of the above study suggested that TG-induced apoptosis and differentiation might be mutually associated. However, another study suggested that apoptosis and differentiation were regulated independently based on the expression of an apoptosis inhibitor, Bcl-2, which did not prevent differentiation while it did inhibit apoptosis (Benito et al., 1995) . The fact that TG induces apoptosis but not differentiation of U937 cells in our study establishes that differentiation and apoptosis can be uncoupled. Our data also demonstrate that TG induces marked apoptosis in NB4 and HL60 cells. The NB4 cell line is derived from the malignant promyelocytes of a patient with classical PML-RARa APL, and serves as the major in vitro model of this disease. NB4 cells have a well-characterized differentiation response to atRA that parallels the in vivo response of APL cells to this treatment. Our observation that NB4 cells are highly sensitive to TG-induced apoptosis establishes that this response is not an idiosyncratic effect of the rare variant NPM-RARa fusion. Similarly, since NB4 cells have a promyelocytic phenotype, we also conclude that the TG effect is not limited to cells of the monocyte lineage.
Our observation of TG-induced apoptosis in HL60 cells may be particularly illuminating. Although HL60 cells have a promyelocytic appearance and undergo granulocytic differentiation in response to treatment with atRA, the line is not APL-derived and does not express an X-RARa fusion protein. Thus, in contrast to our U937 model system where TG sensitivity is indisputably a consequence of NPM-RARa expression, another mechanism must be at work in HL60 cells. We conjecture that the unknown molecular lesion that results in a retinoid-sensitive maturation block in HL60 cells also leads to a phenocopy of the TGsensitivity observed in NPM-RARa and PML-RARa cells. Our observations in the OCI/AML cell lines support this view. The retinoid-sensitive lines AML1, 2, and 3 are also TG sensitive, while the relatively retinoidresistant AML4 line is impervious to the effects of TG treatment. A striking difference is seen, however, in the effects of atRA on TG sensitivity. While in U937/NPMRARa and NB4 cells, concurrent treatment with TG and atRA blocks apoptosis, in HL60 cells there is significant augmentation of apoptosis. The distinction offers insight into the mechanism by which X-RARa expression leads to TG sensitivity. We hypothesize that X-RARa occupies a subset of PPREs, thereby interfering with a portion of the TG response; the PPARgresponsive genes that remain TG responsive in the presence of X-RARa have the net effect of triggering the apoptosis program. Cotreatment with atRA permits the activation of the entire set of PPARg-responsive genes via recruitment of transcriptional coactivators that release the block imposed by X-RARa. The full PPARg response is therefore restored, and apoptosis is not activated.
Although the induction of apoptosis by PPARg ligand has been observed in a number of cancer-derived cell lines, the molecular pathways by which apoptosis is triggered by PPARg activation have not been elucidated. Our experimental model points to a means of resolving this issue. Apoptosis is mediated by caspases, a class of cysteine proteases that cleave key cellular proteins to induce morphological features of nuclear condensation and fragmentation. Apoptosis is initiated by two principal pathways. The extrinsic pathway is activated by the ligand binding of death receptors, such as Fas and TNF receptor-1, resulting in the formation of a death-induced signaling complex (DISC) that recruits and activates caspase-8 (Ashkenazi and Dixit, 1998) . The intrinsic pathway emerges from the release of mitochondrial cytochrome c which binds to Apaf-1, and then Apaf-1 promotes the activation of caspase-9 (Joza et al., 2001) . Caspases play a central role in virtually all known apoptotic signaling. Activated caspase-8 and caspase-9 can, in turn, activate downstream effector caspases including caspase-3. Eibl et al. suggested that the PPARg mediated apoptosis in human pancreatic cancer cells was independent of specific caspase-3 (CPP32), one of the strongest mammalian cell-deathinducing proteases (Eibl et al., 2001) . In the present study, treatment of U937/NPM-RARa cells with 30 mM TG was accompanied by an increase in caspase-3 activity (data not shown), but the specific caspase-3 inhibitor Z-DEVD-CHO failed to attenuate TGinduced apoptosis. However, the nonspecific caspase inhibitor Z-VAD-FMK successfully reversed the effects of PPARg activation in leukemia cells, which suggests that other caspases are involved. In this study, we found that caspase-8 was activated within 24 h of TG treatment and peaked at 72 h, whereas caspase-9 was activated from 48 h after treatment. These findings suggest that PPARg-mediated apoptosis in human leukemia cells is caspase-8 and caspase-9 dependent. This study provides not only a profile of caspase activation, but also the demonstration that both death receptor and mitochondrial pathways can play an essential role in TG-induced apoptosis.
Our observations that NPM-RARa blocks the activity of a TG-responsive reporter in vitro, and that RXRa/NPM-RARa heterodimer can bind to PPREs, suggest a mechanism for the induction of apoptosis by TG in the presence of X-RARa. We hypothesize that in the presence of X-RARa, the PPARg-mediated TG response is partially blocked, and the resulting change in the balance of gene expression leads to induction of apoptosis. We are currently using microarray gene expression profiling to characterize the differences in TG response in U937 versus U937/NPM-RARa cells. Furthermore, we have established that the TG response may be similarly impaired in other non-APL leukemic cells, as it is in HL60 cells; this will be investigated further using leukemic cell lines and primary patient samples. It remains possible that induction of apoptosis by TG in leukemia cells is PPARg independent. This too will be amenable to experimental testing.
In conclusion, the PPARg ligand TG can inhibit the cellular proliferation of leukemia cells via apoptosis, through activation of both receptor-mediated caspase-8 and mitochondria-mediated caspase-9 pathways. In addition to their role in mediating insulin sensitivity and in lipid metabolism, the PPARg agonists may have utility as chemotherapeutic agents. The idea that PPARg ligand activation could be the target for an anticancer therapy has been supported by studies performed on human liposarcomas, breast, colon, lung and pancreatic tumor cells (Tontonoz et al., 1997; Elstner et al., 1998 Elstner et al., , 2002 Mueller et al., 1998; Kitamura et al., 1999; Tsubouchi et al., 2000; Eibl et al., 2001) . Our experimental study using PPARg ligands in human leukemia cell lines suggests the possibility of a novel therapeutic approach to the treatment of AML in cases where traditional therapy is not effective.
Materials and methods
Reagents
The ligands used in this study were TG (Parke-Davis/WarnerLambert, Ann Arbor, MI, USA) which was dissolved in a solution containing 50% dimethyl sulfoxide (DMSO) and 50% ethanol; atRA (Sigma) which was dissolved in 100% DMSO; and 1a, (1,25(OH) 2 D 3 ) (Calbiochem, San Diego, CA, USA) which was dissolved in 100% ethanol.
Cell culture
U937, NB4 and HL60 cells were obtained from American Type Culture Collection (ATCC, Manassas, VA, USA) and were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS). NIH/3T3 and COS-7 cells were obtained from ATCC and maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS. Human 293-derived retroviral packaging cell line (293GPG) was provided by R Mulligan (Harvard University) and maintained in DMEM containing 10% FBS, 1 mg/ml tetracycline, 2 mg/ml puromycin and 0.3 mg/ml G418. Human AML cell lines OCI/AML1-5, provided by Dr MD Minden, were established at the Ontario Cancer Institute, Toronto, Canada (Wang et al., 1989; Koistinen et al., 1991; Yang et al., 1993) . AML2, 3 cells were maintained in a-minimal essential medium (a-MEM) supplemented with 10% FBS, and AML1, 4, 5 cells were grown in a-MEM with 20% FBS and 10% conditional medium of cell line 5637.
Construction of U937/NPM-RARa cell lines
U937 cells were used to produce U937/NPM-RARa cell lines carrying a V5 epitope tag. Briefly, an NPM-RARa expression plasmid was cloned into a pcDNA3.1 V5/HIS vector (Invitrogen) as described (Hummel et al., 2002) . It was then subcloned into the BamHI and NcoI sites of an MMP retrovector (Rebel et al., 1999) to generate NPM-RARa/MMP. An IRES (internal ribosome entry sequence)-GFP insert was added at an MroI site to create an NPM-RARa/MMP construct containing GFP. VSV-G pseudotyped retrovirus was generated as described (Ory et al., 1996) . Briefly, 293GPG cells were transfected with 25 mg MMP plasmid DNA (GFP, NPMRARa/GFP) using lipofectamine (Gibco BRL) according to the manufacturer's protocol. Viral supernatant was collected every 24 h from days 2 to 7, mixed and centrifuged at 22 000 r.p.m. for 2 h. Pellets were resuspended in 50 ml of TNE buffer (50 mM Tris-HCl, pH7.8, 130 mM NaCl, 1 mM EDTA) and kept at 41C overnight, then at À701C for storage. The titers of the concentrated retroviral supernatant were determined by transduction of 1 Â 10 6 NIH/3T3 cells with serial dilutions of supernatant, followed by estimation of the number of infected cells by flow cytometry for GFP. Typical titers were 10 6 -10 7 CFU/ml. For U937 infections, 1 Â 10 6 cells were transduced with 10 4 -10 5 retroviral particles in 1 ml RPMI 1640 medium containing 4 mg/ml polybrene (Sigma). FACS analysis was performed 48 h later and an infection rate of 8% was obtained. U937 cells positive for GFP expression were harvested by sorting. Sorted cells were then plated into methylcellulose containing 30% FBS. Single NPM-RARa clones were isolated after 2 weeks, and expanded in RPMI 1640 medium. Early passages of cells were used for further studies. For use as negative controls, a clone of U937 transduced with GFP/MMP (GFP2) and also a mixed population of GFP/MMP-transduced U937 cells (GFPmix) were maintained.
Western blot analysis
The U973/GFP and U937/NPM-RARa cells were collected and lysed with proteins extraction buffer containing 0.5% deoxycholic acid, 0.1% SDS, 1.0% NP-40 and protease inhibitors (Roche, Germany). Proteins were separated by 8-12% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to Immun-Blott PVDF membranes (Bio-Rad, Hercules, CA, USA). The blots were blocked with 4% skim milk in PBS, 0.1% Tween 20 (PBS-T) and 1:3000 preimmune goat or mouse serum for 1 h at room temperature, then immunoprobed with primary antibody in PBS-T for 2 h at room temperature. After washing with PBS-T, the blots were incubated for 1 h with horseradish-peroxidase-conjugated anti-mouse or anti-rabbit IgG secondary antibody at 1:6000 dilution (Santa Cruz Biotechnology, Santa Cruz, CA, USA). The blots were developed with chemiluminescence reagent (NENt, Boston, MA, USA). The primary antibodies used in this study were mouse monoclonal anti-V5 (1:2000) (Invitrogen, Netherlands), rabbit polyclonal anti-actin (1:1000) (Sigma-Aldrich Canada, Oakville, ON, Canada), rabbit polyclonal anti-caspase-8 (1:1000) and rabbit polyclonal anti-caspase-9 (1:1000) (BD PharMingen). Densitometric analysis was performed using a computing densitometer and Image Quant TM software 3.0 (Molecular Dynamics).
Cell viability
Triplicate cultures of U937/GFP and U937/NPM-RARa cells were incubated at a concentration of 1 Â 10 5 in the absence or presence of TG (7.5, 30 mM) in 24-well plates. The total number of viable cells were determined in a hemocytometer chamber every 24 h for 4 days. Cell viability was assessed by the trypan blue dye exclusion method.
Cell differentiation
Granulocytic or monocytic differentiation was determined using flow cytometry by assessing the increase in the percentage of cell binding of a monoclonal antibody specific for mature granulocytes and monocytes, CD11b, and a monoclonal antibody specific for the mature monocytic marker CD14. The induction of CD11b and CD14 reflects the intiation of myeloid and monocytic cell differentiation, respectively. Cells treated with or without 1,25(OH) 2 D 3 at 2.5 Â 10 À7 M for 5 days were washed once in PBS containing 0.5% FBS. The cells were then incubated with phycoerythrin (PE)-conjugated mouse anti-human CD11b or CD14 (BD PharMingen) for 30 min at 41C. Control studies were performed using mouse IgG 2a isotype antibody. Fluorescence results were collected and analysed by flow cytometry using FACScan (Becton-Dickinson, San Jose, CA, USA) according to the manufacturer's protocol. Each sample for measurement contained 1 Â 10 4 cells. The morphological changes observed 5 days after the treatment of 1,25(OH) 2 D 3 were evaluated by May-Gru¨nwald-Giemsa (EM Science, Gibbstown, NJ, USA) staining of cytospin preparations of the cells.
Cell cycle analysis
Cells were incubated with or without 30 mM TG for 72 h, then washed with ice-cold PBS, and fixed with 70% ethanol at 41C for at least 4 h. After washing, the cells were stained with 50 mg/ ml propidium iodide (PI, Sigma) and 1 mg/ml DNase-free RNase in PBS containing 0.2% Triton X-100 and 1 mM EDTA at 41C for 30 min. The fluorescence results were collected and analysed by flow cytometry using FACScan. Each sample contained 1 Â 10 4 cells for measurement. G0/G1, S and G2/M fractions were identified in the cell cycle profile, and apoptosis was determined by the proportion of sub-G0/G1 (subdiploid) cells.
Detection of apoptosis by annexin V staining
Double staining of annexin V-PE (BD PharMingen) and 7-amino-actinomycin (7-AAD) (BD PharMingen) was performed as follows. Cells were incubated in the presence or absence of 30 mM TG and collected at 24, 48 and 72 h after treatment, then washed with ice-cold PBS, and resuspended in 1 Â binding buffer containing 10 mM HEPES, pH 7.4, 140 mM NaCl, 2.5 mM CaCl 2 at a concentration of 1 Â 10 6 cells/ml. The cell suspension (100 ml) was then transferred to a separate tube and stained with 5 ml annexin V-PE and 5 ml 7-AAD at room temperature for 15 min in the dark. 1 Â binding buffer (400 ml) was added to each tube before the samples were analysed by flow cytometry. The fluorescence results were collected and analysed by FACScan. Control studies were performed with unstained cells, cells stained with annexin V-PE alone and cells stained with 7-AAD alone.
Transient transfection and luciferase reporter assay COS-7 cells were seeded in six-well plates at a density of 5 Â 10 5 cells/well and were incubated overnight for cell attachment. The cells were transiently transfected using Effectene (Qiagen) according to the manufacturer's recommendations. COS-7 cells were cotransfected with 250 ng of reporter plasmid PPRE3-tk-luc (from Dr R Evans, La Jolla, CA, USA), 500 ng of either expression vector pSG5 or pSG5/NPM-RARa plasmid and 250 ng of b-galactosidase expression vector (pCH110, Pharmacia). Cells were allowed to recover overnight and triplicate dishes were treated with or without TG (50 mM). After 48 h, cells were harvested in 200 ml of reporter lysis buffer (Promega). Luciferase activity was measured in a luminometer (Lumat LB9501, Germany). The transfection efficiencies were normalized relative to b-galactosidase activity.
Electrophoretic mobility-shift assay NPM-RARa and RXRa in vitro synthesized proteins were produced using TNT s T7 quick coupled transcription/ translation system according to the manufacturer's manual (Promega). The oligonucleotide PPRE (5 0 -TTCCCGAACGT-GACCTTTGTCCTGGTCCCCTTTTGCTC-3 0 ) and its complement were annealed and 32 P-end-labeled with T4 polynucleotide. In each reaction, an equal amount of in vitro translated proteins was incubated with 32 P-labeled probe (B20 000 c.p.m.) for 30 min at room temperature in buffer (10 mM Tris-HCl, pH 7.5; 4% glycerol; 1 mM MgCl 2 ; 0.5mM EDTA; 0.5 mM DTT; 50 mM NaCl; 0.05 mg/ml poly(dIdC)(Pharmacia)). Samples were further incubated at room temperature for 20 min with 1 ml of the appropriate antibody used for supershift. The antibodies used for supershift were preimmune serum (PI), rabbit polyclonal anti-RARa and antiRXRa (Santa Cruz Biotechnology, Inc.). Protein-DNA complexes were resolved on 6% polyacrylamide gels equilibrated in 0.5 Â TBE and run at 25 mA. The gels were fixed in 10% acetic acid/30% methanol for 15 min, dried and autoradiographed at À801C.
